KR20140048908A - Topical formulation to be applied to wart removal, nail-disease treatment and nail care - Google Patents
Topical formulation to be applied to wart removal, nail-disease treatment and nail care Download PDFInfo
- Publication number
- KR20140048908A KR20140048908A KR1020140026061A KR20140026061A KR20140048908A KR 20140048908 A KR20140048908 A KR 20140048908A KR 1020140026061 A KR1020140026061 A KR 1020140026061A KR 20140026061 A KR20140026061 A KR 20140026061A KR 20140048908 A KR20140048908 A KR 20140048908A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- nail
- oil
- treatment
- topical
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract description 31
- 201000010153 skin papilloma Diseases 0.000 title abstract description 22
- 208000000260 Warts Diseases 0.000 title abstract description 21
- 208000026721 nail disease Diseases 0.000 title abstract description 12
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 claims abstract description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims abstract description 16
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 13
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001630 malic acid Substances 0.000 claims abstract description 13
- 235000011090 malic acid Nutrition 0.000 claims abstract description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000654 additive Substances 0.000 claims abstract description 9
- 239000011975 tartaric acid Substances 0.000 claims abstract description 9
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 9
- 235000015165 citric acid Nutrition 0.000 claims abstract description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 7
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 230000000699 topical effect Effects 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 16
- 239000002253 acid Substances 0.000 abstract description 7
- 206010017533 Fungal infection Diseases 0.000 abstract description 4
- 208000031888 Mycoses Diseases 0.000 abstract description 4
- 210000000003 hoof Anatomy 0.000 abstract description 4
- 244000144972 livestock Species 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
- 206010061304 Nail infection Diseases 0.000 abstract description 2
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 abstract 2
- 210000000078 claw Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- -1 amphoteric Tericin Chemical compound 0.000 description 45
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical class CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 44
- 210000000282 nail Anatomy 0.000 description 31
- 235000007586 terpenes Nutrition 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 229940121375 antifungal agent Drugs 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 239000003429 antifungal agent Substances 0.000 description 14
- 239000010677 tea tree oil Substances 0.000 description 13
- 229940111630 tea tree oil Drugs 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 229960004022 clotrimazole Drugs 0.000 description 10
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 150000003505 terpenes Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000010639 cypress oil Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 6
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 6
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- 229930182821 L-proline Natural products 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229960004130 itraconazole Drugs 0.000 description 6
- 229960004125 ketoconazole Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960004849 isoconazole Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 4
- HDNFMKOSKDGYQQ-UHFFFAOYSA-N 2-[(2-chlorophenyl)-diphenylmethyl]-1h-imidazole Chemical compound ClC1=CC=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=NC=CN1 HDNFMKOSKDGYQQ-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 210000004906 toe nail Anatomy 0.000 description 4
- MPIPASJGOJYODL-UHFFFAOYSA-N 1-{2-[(2,6-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Natural products C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229960003662 desonide Drugs 0.000 description 3
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 3
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical group CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010068058 Nail atrophy Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- QNXUUBBKHBYRFW-QWAPGEGQSA-N formocortal Chemical compound C1C(C=O)=C2C=C(OCCCl)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O QNXUUBBKHBYRFW-QWAPGEGQSA-N 0.000 description 2
- 229960000671 formocortal Drugs 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- FBVVGPMIPAZFAW-WCCKRBBISA-N pyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-WCCKRBBISA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010678 thyme oil Substances 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical group C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Chemical group C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Chemical group C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AVKUERGKIZMTKX-YXLKDIQASA-N (2s,5r)-6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)NC(=O)C(N)C1=CC=CC=C1 AVKUERGKIZMTKX-YXLKDIQASA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- CPUKWYXYHPOQJH-RDQPJNLGSA-N (8r,9s,10s,13s,14s)-17-ethenyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)C=C)[C@@H]4[C@@H]3CCC21 CPUKWYXYHPOQJH-RDQPJNLGSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical group C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LAJYZDROZWKLMW-UHFFFAOYSA-N 1-phenoxyethanol;2-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.OCCOC1=CC=CC=C1 LAJYZDROZWKLMW-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- YUTUUOJFXIMELV-UHFFFAOYSA-N 2-Hydroxy-2-(2-methoxy-2-oxoethyl)butanedioic acid Chemical compound COC(=O)CC(O)(C(O)=O)CC(O)=O YUTUUOJFXIMELV-UHFFFAOYSA-N 0.000 description 1
- ZRADTNJSPQDCDV-UHFFFAOYSA-N 2-butyl-4-methoxyphenol Chemical compound CCCCC1=CC(OC)=CC=C1O ZRADTNJSPQDCDV-UHFFFAOYSA-N 0.000 description 1
- KUNNUNBSGQSGDY-UHFFFAOYSA-N 2-butyl-6-methylphenol Chemical compound CCCCC1=CC=CC(C)=C1O KUNNUNBSGQSGDY-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- SLXNXGGPCQWSQY-UHFFFAOYSA-N 2-methylquinolin-4-amine hydrate Chemical compound O.C1=CC=CC2=NC(C)=CC(N)=C21 SLXNXGGPCQWSQY-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- FHHFKGGCXNOIAY-UHFFFAOYSA-N 4-ethoxy-3-hydroxy-4-oxobutanoic acid Chemical compound CCOC(=O)C(O)CC(O)=O FHHFKGGCXNOIAY-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WNPVZANXRCPJPW-UHFFFAOYSA-N 5-[isocyano-(4-methylphenyl)sulfonylmethyl]-1,2,3-trimethoxybenzene Chemical compound COC1=C(OC)C(OC)=CC(C([N+]#[C-])S(=O)(=O)C=2C=CC(C)=CC=2)=C1 WNPVZANXRCPJPW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- KGNQFVOROXFGAU-RSSWFWKPSA-N Amorphigenol O-vicianoside Chemical compound O([C@H](C([C@@H](O)[C@@H]1O)O)OC(C)(CO)C2CC3=C4OC5COC=6C=C(C(=CC=6C5C(=O)C4=CC=C3O2)OC)OC)C1CO[C@@H]1OC[C@H](O)C(O)C1O KGNQFVOROXFGAU-RSSWFWKPSA-N 0.000 description 1
- UTJHAADBJGQRKW-UHFFFAOYSA-N Amorphol Natural products COc1cc2OCC3Oc4c5CC(Oc5ccc4C(=O)C3c2cc1OC)C(C)COC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O UTJHAADBJGQRKW-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- HEYZCPGDZRAHDD-UHFFFAOYSA-N COCCO.COC(C)O Chemical compound COCCO.COC(C)O HEYZCPGDZRAHDD-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 235000010701 Lavanda vera Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010048886 Onychoclasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Chemical group C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Chemical group C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 125000003447 alpha-pinene group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Chemical group 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Chemical group C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- RFAZFSACZIVZDV-UHFFFAOYSA-N butan-2-one Chemical compound CCC(C)=O.CCC(C)=O RFAZFSACZIVZDV-UHFFFAOYSA-N 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003950 combination of corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Chemical group C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- NJNWEGFJCGYWQT-VSXGLTOVSA-N fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 1
- 229940094766 flucloronide Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Chemical group C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- UPWGQKDVAURUGE-UHFFFAOYSA-N glycerine monooleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-UHFFFAOYSA-N 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- WJLUBOLDZCQZEV-UHFFFAOYSA-M hexadecyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CCCCCCCCCCCCCCCC[N+](C)(C)C WJLUBOLDZCQZEV-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- YCOFRPYSZKIPBQ-UHFFFAOYSA-N penicillic acid Natural products COC1=CC(=O)OC1(O)C(C)=C YCOFRPYSZKIPBQ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VOUGEZYPVGAPBB-UHFFFAOYSA-N penicillin acid Natural products OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- QZCSUJKMSRTCMX-UHFFFAOYSA-N propan-2-yl pentadecanoate 2-propan-2-yltetradecanoic acid Chemical compound CCCCCCCCCCCCC(C(C)C)C(O)=O.CCCCCCCCCCCCCCC(=O)OC(C)C QZCSUJKMSRTCMX-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RTHJZIYLZCGBCN-UHFFFAOYSA-N thiolan-3-ylurea Chemical compound NC(=O)NC1CCSC1 RTHJZIYLZCGBCN-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 피부 상의 사마귀 제거, 손발톱 질병 치료 및 손발톱 관리를 위한 비수성 국소 도포 약제에 관한 것으로, 보다 상세하게는 하나 혹은 그 이상의 활성 물질, 운반체로서 유산, 사과산, 주석산, 구연산, 운데칸산, 혹은 운데켄산의 C1-C4-알킬에스테르, 및 경우에 따른 생리학적 호환성 보조 첨가제를 포함하는 상기 국소 약제에 관한 것이다.FIELD OF THE INVENTION The present invention relates to non-aqueous topical application for the removal of warts on the skin, treatment of nail disease, and nail care, and more particularly one or more active agents, carriers as lactic acid, malic acid, tartaric acid, citric acid, undecanoic acid, or The topical medicament comprises a C 1 -C 4 -alkylester of undekenic acid, and optionally a physiologically compatible auxiliary additive.
또한, 본 발명은 상기 제형을 제조하기 위한 방법 및 그 용도에 관한 것이다.The invention also relates to a method for the preparation of said formulations and to the use thereof.
사마귀(Verruca)는 각질층이 강하게 두꺼워진 상태에서 진피 유두(dermal papilla)가 바이러스, 무엇보다 파포바 바이러스를 원인으로 하여 대개 양성으로 증식된 종기이며, 이와 관련하여 상기 각질층은 침투되기 어려우며 케라틴층으로서 지칭된다. 적어도 50개의 상이한 피부 종기는 사마귀로서 분류되며, 100개 이상의 사마귀 바이러스에 의해, 다시 말해 유두종 바이러스의 균주에 의해 야기될 수 있다. 그 구분에 있어서 선충형 사마귀가 있는데, 이는 얼굴, 목 혹은 눈꺼풀에서 증식하는 길이가 길면서도 폭이 좁은 종기이다. 편평 사마귀(plantar wart)는 얼굴, 손등, 목 혹은 가슴에서 생성된다. 이러한 사마귀들은 긁거나 간단하게 면도를 하는 것만으로도 확산될 수 있다. 또한, 꽃양배추 모양으로 보이면서 머리나 목 부위에 나타나는 줄기가 있는 사마귀와 손가락과 손에 무엇보다 손톱 주변에서 종종 발견하게 되는 조갑주위 사마귀가 발생한다. 가시 사마귀(thorny wart)는 종종 발바닥에 생기고 치료가 어렵다. 공지된 점에 따라서 사마귀 및 손발톱 질병의 국소 치료 또는 손발톱 관리는 부작용 없이 이루어지면서 적은 비용으로 간단하게 시술된다. 그러나, 사마귀를 제거하기 위해 손발톱 조성물을 적용하는 경우, 충분한 양의 활성 물질, 영양 물질 및 재생 물질을 사마귀의 각질층 또는 손톱을 통과하여 보다 깊은 곳에 위치하는 치료할 조직층으로 침투시키고, 그곳에 위치하는 병원체, 예컨대 바이러스 또는 진균을 완전하게 소멸시켜야 하는 문제가 있다. 비록 통상적인 약제를 이용하여 존재하는 병원체에 부분적으로 도달시켜 직접적인 국소 치료를 통해 증상을 소멸시킬 수 있기는 하지만, 그러나 대부분의 경우에 치료를 중단하게 되면 증상은 다시 발생한다. 치료할 사마귀의 경우 다소의 자연 요법이 공지되어 있는데, 그러나 이런 요법은 성공을 보장하지 못하며 피부층 및 각질층의 침투에 문제가 있었다.Verruca is a boil that is usually positively proliferated by dermal papilla caused by a virus, most of all, papova virus in a state where the stratum corneum is strongly thickened. In this regard, the stratum corneum is difficult to penetrate and is a keratin layer. It is referred to. At least 50 different skin boils are classified as warts and can be caused by more than 100 wart viruses, in other words by strains of papilloma virus. There are nematode warts in this division, which are long and narrow boils that multiply in the face, neck or eyelids. Plantar warts are produced on the face, back of the hand, neck or chest. These warts can spread simply by scratching or simply shaving. In addition, cauliflower-like warts appear on the head or neck, and around the fingernails and fingertips, most often found around the nails. Thorny warts often occur on the soles of the feet and are difficult to treat. According to what is known, topical treatments or nail care of warts and nail diseases are simply performed at low cost, with no side effects. However, when applying the nail composition to remove warts, a sufficient amount of active, nutritional and regenerating material passes through the stratum corneum or nail of the wart into a deeper layer of the tissue to be treated, where the pathogen is located, For example, there is a problem of completely extinguishing a virus or a fungus. Although conventional agents can be used to partially reach existing pathogens and eliminate the symptoms through direct local therapy, in most cases the symptoms recur when the treatment is discontinued. Some natural remedies are known for the warts to be treated, but these therapies do not guarantee success and have problems with penetration of the skin and stratum corneum.
이른바 운반체, 다시 말해 활성 물질에 대한 우수한 용해성과 더불어 각질층 및 손발톱 성분에 대한 우수한 침투성 뿐 아니라 상기 활성 물질을 손발톱 조직을 통과시켜 운반하는 능력을 구비한 물질과 함께, 활성 물질을 적용함으로써, 활성 물질의 직접적인 국소 도포 시 치료 결과를 개선하는 것은 이미 제안되어 있다. 예를 들어, EP-A-0 503 988로부터는 손발톱 진균증을 치료하기 위한 약제가 개시되는데, 상기 약제는 항진균성 활성 물질, 및 항진균제가 적어도 부분적으로 용해될 수 있는 수성 매체와 더불어, 손발톱에 대한 항진균제의 침투를 촉진시키는 적어도 하나의 친수성 물질을 함유하고 있다. 침투 촉진 물질로서 다수의 화합물과 함께 유산 에틸에스테르 또한 제시된다. EP-A-0 503 988에 기술된 제형 원리는 활성 물질용으로 당연히 요구되는 부분적인 수용성으로 인해 오로지 제한된 수의 활성 물질에만 적용될 수 있다. 그 외에도, 상기 원리에 따라 제형의 물 함유로 인해 유산 에틸에스테르와 같은 침투 촉진 물질로서 가수분해성 화합물을 이용할 시에 안정된 제형을 제조할 수 없는데, 왜냐하면 상기 화합물은 저장 시간동안 가수분해에 의해 분해되기 때문이다.By applying the active substance together with a so-called carrier, that is, a substance having the ability to carry the active substance through the nail tissue, as well as a good solubility in the active substance, as well as good permeability to the stratum corneum and nail components, the active substance It has already been proposed to improve the treatment outcomes upon direct topical application of. For example, EP-A-0 503 988 discloses a medicament for treating nail fungus, which, together with an antifungal active substance, and an aqueous medium in which the antifungal agent can be at least partially dissolved, It contains at least one hydrophilic substance that promotes penetration of antifungal agents. Lactic acid ethyl esters are also shown with many compounds as penetration promoting materials. The formulation principle described in EP-A-0 503 988 can be applied only to a limited number of active substances due to the partial water solubility naturally required for the active substances. In addition, according to the above principle, due to the water content of the formulation, it is not possible to prepare a stable formulation when using a hydrolyzable compound as a penetration promoting substance such as lactic acid ethyl ester, because the compound is decomposed by hydrolysis during storage time. Because.
지금까지, 손발톱 질병의 국소 치료 혹은 국소적 손발톱 관리를 위한 약제와 관련하여, 지속적인 치료 결과를 위해 요구되는 량의 활성 물질을 손발톱을 통과해서 그 아래 위치하는 조상 및 조근(조모)까지 운반하는 점을 보장하는 운반체를 함유하는 만족스러운 상기 약제는 공지되지 않았다.To date, with respect to the topical treatment of nail disease or for the treatment of local nail care, the transport of the required amount of active substance through the nail to the ancestors and ancestors (grandparents) located below it for sustained treatment outcomes Satisfactory medicaments containing a carrier which ensures that are not known.
그러므로, 본 발명은 사마귀 제거, 손발톱 질병의 국소 치료, 및 국소적 손발톱 관리와 관련하는 문제를 해결하면서, 신속하면서도 지속적인 치료 결과를 가능케하는 약학상의 약제 또는 화장용 약제를 제공하는 것을 그 목적으로 한다.It is therefore an object of the present invention to provide a pharmaceutical or cosmetic medicament that enables rapid and sustained treatment results while solving problems associated with wart removal, topical treatment of nail disease, and topical nail care. .
본 발명에 따라 사마귀 제거, 손발톱 질병 치료 및 손발톱 관리를 위한 비수성 국소 도포 약제가 제안된다. 이와 관련한 상기 국소 약제는 하기의 조성을 갖는다:According to the present invention a non-aqueous topical topical agent for wart removal, nail disease treatment and nail care is proposed. The topical agent in this regard has the following composition:
a) 하나 혹은 그 이상의 활성 물질,a) one or more active substances,
b) 운반체로서, 유산, 사과산, 주석산, 구연산, 운데칸산, 혹은 운데켄산의 C1-C4-알킬에스테르, 및 b) C 1 -C 4 -alkyl esters of lactic acid, malic acid, tartaric acid, citric acid, undecanoic acid, or undecanoic acid, as carriers, and
c) 경우에 따라 생리학적 호환성 보조 첨가제.c) Optionally, physiologically compatible auxiliary additives.
본 발명에 따른 비수성 국소 도포 약제의 경우, 치료를 위해 기본적으로 사마귀(피부 종기)에서 손발톱 질병 및 조갑주위 질병에 효과적인 모든 합성 및 천연 활성 물질들이 고려된다. 또한, 활성 물질로서 손발톱 관리 시에 효과적인 영양 및 재생 물질이 고려된다. 사마귀 제거를 위해 특히 바람직한 것은 측백나무 오일(thuja oil)의 조성물이다.In the case of the non-aqueous topical medicament according to the present invention, all synthetic and naturally active substances that are effective for treatment are essentially effective for nail disease and peripheral disease in warts (skin boils). Also considered are active nutritional and regenerative materials which are effective in nail care as the active substance. Particularly preferred for wart removal is a composition of thuja oil.
본 발명에 따른 약제 내에 함유될 수 있는 적합한 활성 물질은 합성 및 천연 항진균제, 항생제, 방부제, 코르티코스테로이드, 영양 물질 및 재생 물질 뿐 아니라 전술한 활성 물질의 조합물이다. 상기 활성 물질에 대한 특별한 예는 하기와 같다:Suitable active substances which may be contained in the medicaments according to the invention are synthetic and natural antifungal agents, antibiotics, preservatives, corticosteroids, nutritional substances and regenerative substances as well as combinations of the aforementioned active substances. Specific examples of such active substances are as follows:
- 항진균제 및 그 생리학적 호환성 염: 예컨대 (±)-시스-2,6-디메틸-4-[2-메틸-3-(p- tert-펜틸-페닐)프로필]모르폴린(아모롤핀), 암포테리신, 6-사이클로헥실-1-하이드록시-4-메틸-2(1H)-피리디논(시클로피록스), 비스-페닐-(2-클로로페닐)-1-이미다졸릴메탄(클로트리마졸), 1-[2-(2,4-디클로로페닐)-2-(4-클로로벤질옥시)-에틸]-이미다졸(에코나졸), 2,4-디플루오르-α,α-비스(1H-1,2,4-트리아졸-1-일메틸)벤질알코올(풀루코나졸), 5-플루오르사이토신(플루시토신), 7-클로로-트리메톡시-메틸스피로-[벤조푸란-사이클로헥센]-디온(그리세오풀빈), 1-[2,4-디클로로-β-(2,6-디클로로벤질옥시)-펜에틸]-이미다졸(이소코나졸), (±)-1-sec-부틸-4-{4-[4-(4-{[(2R*,4S*)-2-(2,4-디클로로페닐)-2-(1,2,4-트리아졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시}페닐)-1-피페라지닐]페닐}-4,5-디하이드로-1,2,4-트리아졸-5-온(이트라코나졸), (±)-시스-1-아세틸-4-{4-([2-(2,4-디클로로페닐)-2-(1H-이미다졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시)페닐}피페라진(케토코나졸), 1-[2,4-디클로로-β-(2,4-디클로로 벤질옥실)-펜에틸]-이미다졸(미코나졸), (E)-N-신나밀-N-메틸-1-나프틸메틸아민(나프티핀), 니스타틴, (E)-N-(6,6-디메틸-2-헵텐-4-이닐)-N-메틸-1-나프틸메틸아민(테르비나핀), 1[2-{(2-클로로-3-티에닐)메톡시}-2-(2,4-디클로로페닐)에틸]-1H-이미다졸(티오코나졸), O-2-나프틸-N-메틸-N-(3-톨릴)-티오카르바메이트(톨나프테이트), α-(2,4-디플루-오로페닐)-5-플루오로-β-메틸-α-(1H-1,2,4-트리아졸-1-일메틸)-4-피리미딘에탄올(보리코나졸)이 있다.Antifungal agents and physiologically compatible salts thereof: for example (±) -cis-2,6-dimethyl-4- [2-methyl-3- ( p- tert -pentyl-phenyl) propyl] morpholine (amorphol), amphoteric Tericin, 6-cyclohexyl-1-hydroxy-4-methyl-2 (1H) -pyridinone (cyclopyrox), bis-phenyl- (2-chlorophenyl) -1-imidazolylmethane (clotritri Mazol), 1- [2- (2,4-dichlorophenyl) -2- (4-chlorobenzyloxy) -ethyl] -imidazole (econazole), 2,4-difluoro-α, α-bis ( 1 H- 1,2,4 - triazol-1 - ylmethyl) benzyl alcohol (pulluconazole), 5-fluorocytosine (flucitosine), 7-chloro-trimethoxy-methylspiro- [benzofuran- Cyclohexene] -dione (griseofulvin), 1- [2,4-dichloro-β- (2,6-dichlorobenzyloxy) -phenethyl] -imidazole (isoconazole), (±) -1- sec-butyl-4- {4- [4- (4-{[(2R *, 4S *)-2- (2,4-dichlorophenyl) -2- (1,2,4-triazole-1- Monomethyl) -1,3-dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl] phenyl} -4,5-dihydro-1,2,4-triazole -5-one (itraconazole), (±) -cis-1-acetyl-4- {4-([2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl)- 1,3-dioxolan-4-yl] methoxy) phenyl} piperazine (ketoconazole), 1- [2,4-dichloro-β- (2,4-dichloro benzyloxyl) -phenethyl] -imidazole ( miconazole), (E) -N- cinnamyl - N - methyl-1-naphthyl methylamine (naphthyridin-pin), did statins, (E) - N- (6,6- dimethyl-2-heptene-4 Inyl) -N- methyl-1-naphthylmethylamine (terbinafine), 1 [2-{(2-chloro-3-thienyl) methoxy} -2- (2,4-dichlorophenyl) ethyl] -1H-imidazole (thioconazole), O-2-naphthyl-N-methyl-N- (3-tolyl) -thiocarbamate (tolnaphate), α- (2,4-diflu- Orophenyl) -5-fluoro-β-methyl-α- (1H-1,2,4-triazol-1-ylmethyl) -4-pyrimidinethanol (voriconazole).
- 천연 항진균제: 예컨대, 에테르유 및 식물 추출물이 있다.Natural antifungal agents: for example ether oils and plant extracts.
- 항생제 및 그 생리학적 호환성 염: 예컨대, α-아미노-4-하이드록시 벤질 페니실린(아목시실린), D-(-)-α-아미노 벤질 페니실린(암피실린), 3,3-디메틸-7-옥소-6-페닐아세트아미도-4-티아-1-아자바이시클로-[3.2.0]-헵탄-2-카르본산(벤질 페니실린), 벤질 페니실린-벤자틴, 3-클로로-7-D(2-페닐 글리신아미도)-세팔로스포란산(세파클로르), 7β-[D-2-아미노-(4-하이드록시페닐)-아세틸아미노]-3-메틸-세팔로스포란산(세파드록실), 아미노페닐-아세트아미도-메틸-세팔로스포란산(세파렉신), D(-)-트레오-2-디클로로아세트아미도-1-(4-니트로페닐)-1,3-프로판디올(클로르암페니콜), 1-시클로프로필-6-플루오르-1,4-디하이드로-4-옥소-7-(1-피페라지닐)-3-퀴놀린카르본산(시프로플록사신), (Z)-(2R,5R)-3-(2-하이드록시에틸리덴)-7-옥소-4-옥사-1-아자바이시클로[3.2.0]헵탄-2-카르본산(클라불란산), 7-클로로-7-데속시-린코마이신(클린다마이신), 6-데속시-5-하이드록시 테트라시클린(독시시클린), 1-에틸-6-플루오르-1,4-디하이드로-4-옥소-7-(1-피페라지닐)-1,8-나프티리딘-3-카르본산(에녹사신), 에리트로마이신, 3-(2-클로로-6-플루오르페닐)-5-메틸-4-이속사졸릴-페니실린(플루클록사실린), 카나마이신, 린코마이신, 7-디메틸아미노-6-데속시-6-데스메틸 테트라시클린(미노시클린), 6-(2-에톡시-1-나프트 아미도)-페니실린(나프실린), 1-에틸-1,4-디하이드로-7-메틸-4-옥소-1,8-나프티리딘-3-카르본산(날리딕신산), 네오마이신, 1-에틸-6--플루오로-1,4-디하이드로-4-옥소-7-(1-피페라지닐)-3-퀴놀린카르본산(노르플록사신), (±)-9-플루오르-2,3-디하이드로-3-메틸-10-(4-메틸-1-피페라지닐)-7-옥소-7H-피리도[1,2,3-데][1,4]벤족사진-6-카르본산(오플록사신), 6-(5-메틸-3-페닐-4-이속사졸 카르복스아미도)페니실린산(옥사실린), 6-페녹시아세틸아미노-페니실린산(페녹시 메틸 페니실린), 4-디메틸아미노-옥타하이드로-펜타하이드록시-1,11-디옥소-6-메틸-나프트아센-2-카르바미드(테트라시클린)이 있다.Antibiotics and physiologically compatible salts thereof: for example, α-amino-4-hydroxy benzyl penicillin (amoxicillin), D-(-)-α-amino benzyl penicillin (ampicillin), 3,3-dimethyl-7-oxo- 6-phenylacetamido-4-thia-1-azabicyclo- [3.2.0] -heptane-2-carboxylic acid (benzyl penicillin), benzyl penicillin-benzatin, 3-chloro-7-D (2- Phenyl Glycinamido) -Cephalosporanic Acid (Sephachlor), 7β- [D-2-Amino- (4-hydroxyphenyl) -acetylamino] -3-methyl-Sephalosporranic Acid (Sepadroxyl ), Aminophenyl-acetamido-methyl-cephalosporanic acid (separexin), D (-)-threo-2-dichloroacetamido-1- (4-nitrophenyl) -1,3-propanediol (Chloramphenicol), 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (ciprofloxacin), (Z)- (2R, 5R) -3- (2-hydroxyethylidene) -7-oxo-4-oxa-1-azabicyclo [3.2.0] heptane-2-carboxylic acid (clavula Lanic acid), 7-chloro-7-decoxy-lincomycin (Clindamycin), 6-decoxy-5-hydroxy tetracycline (doxycycline), 1-ethyl-6-fluoro-1,4-dihydro -4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid (enoxacin), erythromycin, 3- (2-chloro-6-fluorophenyl) -5-methyl 4-isoxazolyl-penicillin (flucloxacillin), kanamycin, lincomycin, 7-dimethylamino-6-desoxy-6-desmethyl tetracycline (minocycline), 6- (2-ethoxy -1-naft amido) -penicillin (naphcillin), 1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid (nalidic acid) , Neomycin, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (norfloxacin), (±)- 9-Fluoro-2,3-dihydro-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-7 H- pyrido [1,2,3- de ] [1, 4] benzoxazine-6-carboxylic acid (ofloxacin), 6- (5-methyl-3-phenyl-4- Isoxazole carboxamido) penicillic acid (oxacillin), 6-phenoxyacetylamino-phenicylic acid (phenoxy methyl penicillin), 4-dimethylamino-octahydro-pentahydroxy-1,11-dioxo-6 -Methyl-naphthacene-2-carbamide (tetracycline).
- 방부제: 예컨대, 알킬벤질 디메틸 암모늄 클로라이드(벤잘코늄-클로라이드), N-벤질-N,N-디메틸-2-{2-[p-(1,1,3,3-테트라메틸부틸)-페녹시]-에톡시}-에틸 암모늄 하이드록시드(벤제토늄 클로라이드),세틸트리메틸 암모늄 하이드록시드(세트리모늄 브로미드), 1,1'-헥사메틸렌-비스-[5-(p-클로로페닐)-비구아니드](클로르헥시딘), N1,N1-데카메틸렌-비스-(4-아미노 퀴날디늄 하이드록시드)(디퀄리늄 클로라이드; dequalinium chloride), N-(4-클로로페닐)-N'-(3,4-디클로로페닐)요소(트리클로카르반), 5-클로로-2-(2,4-디클로로페녹시)페놀(트리클로산; Triclosan)이 있다.Preservatives: for example alkylbenzyl dimethyl ammonium chloride (benzalkonium-chloride), N-benzyl-N, N-dimethyl-2- {2- [p- (1,1,3,3-tetramethylbutyl) -phenoxy -Ethoxy} -ethyl ammonium hydroxide (benzetonium chloride), cetyltrimethyl ammonium hydroxide (cetrimonium bromide), 1,1'-hexamethylene-bis- [5- (p-chlorophenyl ) -Biguanide] (chlorhexidine), N 1 , N 1 -decamethylene-bis- (4-amino quinaldinium hydroxide) (diqualium chloride; dequalinium chloride), N- (4-chlorophenyl) -N '-(3,4-dichlorophenyl) urea (triclocarban), 5-chloro-2- (2,4-dichlorophenoxy) phenol (triclosan).
- 코르티코스테로이드 및 그 생리학적 호환성 염: 예컨대 9α-클로로-16β-메틸프레드니솔론(베클로메타손), 9-플루오르-11β,17,21-트리하이드록시-16β-메틸-1,4-프레그나디엔(pregnadien)-3,20-디온(베타메타손), 21-클로로-9-플루오르-11β,17-디하이드록시-16β-메틸-1,4-프레그나디엔-3,20-디온(클로베타솔), 17,21-디하이드록시-프레근(pregn)-4-엔-3,11,20-트리온(코르티손), 11β,16α,17α,21-테트라하이드록시-1,4-프레그나디엔-3,20-디온-16,17-아세톤아세탈(데소나이드), 9-플루오르-11β-17,21-트리하이드록시-16α-메틸프레그나-1,4-디엔-3,20-디온(덱사-메타손), 9α,11β-디클로로-6α-플루오로-21-하이드록시-16α,17α-(이소프로필리덴디옥시)-프레그나-1,4-디엔-3,20-디온(플루클로로나이드; flucloronide), 6α,9α-디플루오르-16α,17α-이소프로필리덴디옥시-코르티코스테론(플루오시놀론 아세토나이드), 6α,9α-디플루오르-16α,17α-이소프로필리덴디옥시-코르티코스테론-아세테이트(플루오시노나이드), 6α-플루오르-11β,21-디하이드록시-16α,17-이소프로필리덴디옥시-4-프레그넨-3,20-디온(플루드록시코르티드; fludroxycortide), 3-(2-클로로에톡시)-9α-플루오로-6-포르밀-11β,21-디하이드록시-16α,17α-이소프로필리덴 디옥시프레그나-3,5-디엔-20-온(포르모코르탈), 21-클로로-9α-플루오르-11β-하이드록시-16α,17α-이소프로필리덴디옥시-4-프레그넨-3,20-디온(할시노나이드), 17α-하이드록시 코르티코스테론(하이드로코르티손), 11β,17,21-트리하이드록시-6α-메틸-1,4-프레그나디엔-3,20-디온(메틸프레드니솔론), 11β,17,21-트리하이드록시-프레그나-1,4-디엔-3,20-디온(프레드니솔론), 17α,21-디하이드록시-프레그나-1,4-디엔-3,11,20-트리온(프레드니손), 9-플루오르-16α-하이드록시 프레드니솔론(트리암시놀론), 및 트리암시놀론-16α,17α-아세토나이드(트리암시놀론 아세토나이드)가 있다.Corticosteroids and physiologically compatible salts thereof: for example 9α-chloro-16β-methylprednisolone (veclomethasone), 9-fluor-11β, 17,21-trihydroxy-16β-methyl-1,4-preg Nadiene (pregnadien) -3,20-dione (betamethasone), 21-chloro-9-fluor-11β, 17-dihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione ( Clobetasol), 17,21-dihydroxy-pregn-4-ene-3,11,20-trione (cortisone), 11β, 16α, 17α, 21-tetrahydroxy-1,4 -Pregnadiene-3,20-dione-16,17-acetone acetal (desonide), 9-fluoro-11β-17,21-trihydroxy-16α-methylpregna-1,4-diene-3 , 20-dione (dexsa-methasone), 9α, 11β-dichloro-6α-fluoro-21-hydroxy-16α, 17α- (isopropylidenedioxy) -pregna-1,4-diene-3, 20-dione (fluchlororonide), 6α, 9α-difluoro-16α, 17α-isopropylidenedioxy-corticosterone (fluorocinolone acetona D), 6α, 9α-difluoro-16α, 17α-isopropylidenedioxy-corticosterone-acetate (fluorosinide), 6α-fluor-11β, 21-dihydroxy-16α, 17-isopropyl Dendioxy-4-pregnene-3,20-dione (fludroxycortide), 3- (2-chloroethoxy) -9α-fluoro-6-formyl-11β, 21-dihydroxy- 16α, 17α-isopropylidene dioxypregna-3,5-diene-20-one (formocortal), 21-chloro-9α-fluoro-11β-hydroxy-16α, 17α-isopropylidenedioxy -4-pregnene-3,20-dione (halcinolone), 17α-hydroxy corticosterone (hydrocortisone), 11β, 17,21-trihydroxy-6α-methyl-1,4-pregnadi En-3,20-dione (methylprednisolone), 11β, 17,21-trihydroxy-pregna-1,4-diene-3,20-dione (prednisolone), 17α, 21-dihydroxy-pregna -1,4-diene-3,11,20-trione (prednisone), 9-fluoro-16α-hydroxyprop Rednisolone (triamcinolone), and triamcinolone-16α, 17α-acetonide (triamcinolone acetonide).
본 발명에 따라 바람직한 항진균제는 비스-페닐-(2-클로로페닐)-1-이미다졸릴메탄(클로트리마졸), 1-[2,4-디클로로-β-(2,6-디클로로벤질옥시)-펜에틸]-이미다졸(이소코나졸), 2,4-디플루오르-α,α-비스(1H-1,2,4-트리아졸-1-일메틸)벤질알코올(플루코나졸), (±)-1-sec-부틸-4-{4-[4-(4-{[(2R*,4S*)-2-(2,4-디클로로페닐)-2-(1,2,4-트리아졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시}페닐)-1-피페라지닐]페닐}-4,5-디하이드로-1,2,4-트리아졸-5-온(이트라코나졸), (±)-시스-1-아세틸-4-{4-([2-(2,4-디클로로페닐)-2-(1H-이미다졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시)페닐}피페라진(케토코나졸), 1-[2,4-디클로로-β-(2,4-디클로로벤질옥실)-펜에틸]-이미다졸(미코나졸), (E)-N-(6,6-디메틸-2-헵텐-4-이닐)-N-메틸-1-나프틸메틸아민(테르비나핀), α-(2,4-디플루오로페닐)-5-플루오로-β-메틸-α-(1H-1,2,4-트리아졸-1-일메틸)-4-피리미딘 에탄올(보리코나졸)이다.Preferred antifungal agents according to the invention are bis-phenyl- (2-chlorophenyl) -1-imidazolylmethane (clotrimazole), 1- [2,4-dichloro-β- (2,6-dichlorobenzyloxy) -Phenethyl] -imidazole (isoconazole), 2,4-difluoro-α, α-bis (1H-1, 1,2,4 - triazol-1 - ylmethyl) benzyl alcohol (fluconazole), ( ±) -1- sec -butyl-4- {4- [4- (4-{[(2R *, 4S *)-2- (2,4-dichlorophenyl) -2- (1,2,4- Triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl] phenyl} -4,5-dihydro-1,2,4-triazole -5-one (itraconazole), (±) -cis-1-acetyl-4- {4-([2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl)- 1,3-dioxolan-4-yl] methoxy) phenyl} piperazine (ketoconazole), 1- [2,4-dichloro-β- (2,4-dichlorobenzyloxyl) -phenethyl] -imidazole ( miconazole), (E) - N- (6,6- dimethyl-2-hepten-4-ynyl) - N- methyl-1-naphthyl methylamine (terbinafine), α- (2,4- di Fluorophenyl) -5-fluoro-β-methyl-α- (1H-1,2,4-triazole-1 -Ylmethyl) -4-pyrimidine ethanol (voriconazole).
본 발명에 따라 특히 바람직한 항진균제는 비스-페닐-(2-클로로페닐)-1-이미다졸릴 메탄(클로트리마졸), 1-[2,4-디클로로-β-(2,6-디클로로벤질옥시)-펜에틸]-이미다졸(이소코나졸), (±)-1-sec -부틸-4-{4-[4-(4-{[(2R*,4S*)-2-(2,4-디클로로페닐)-2-(1,2,4-트리아졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시}페닐)-1-피페라지닐]페닐}-4,5-디하이드로-1,2,4-트리아졸-5-온(이트라코나졸), (±)-시스-1-아세틸-4-{4-([2-(2,4-디클로로페닐)-2-(1H-이미다졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시)페닐}피페라진(케토코나졸)이다.Particularly preferred antifungal agents according to the invention are bis-phenyl- (2-chlorophenyl) -1-imidazolyl methane (clotrimazole), 1- [2,4-dichloro-β- (2,6-dichlorobenzyloxy ) phenethyl] imidazole (iso nose or sol), (±) -1- sec-butyl -4- {4- [4- (4 - {[(2R *, 4S *) - 2- (2, 4-dichlorophenyl) -2- (1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy} phenyl) -1-piperazinyl] phenyl}- 4,5-dihydro-1,2,4-triazol-5-one (itraconazole), (±) -cis-1-acetyl-4- {4-([2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy) phenyl} piperazine (ketoconazole).
바람직한 천연 항진균제는 티 트리 오일(멜라루카 알터니폴리아), 라벤더 오일(Lavandula officinalis chaix) 및 ABC-오일(호주 블루 사이프러스 오일 - Callitris Intratropica)이다. 이러한 천연 항진균제들은 개별적인 활성 물질로서 혹은 다수의 상기 활성 물질들의 조합물로서 이용될 수 있다. 바람직한 활성 물질 조합물은 라벤더 오일, 티 트리 오일, 측백나무 오일, 및 ABC-오일의 혼합물이다.Preferred natural antifungal agents are tea tree oil (melaleuca alternifolia), lavender oil (Lavandula officinalis chaix) and ABC-oil (Australian blue cypress oil-Callitris Intratropica). Such natural antifungal agents can be used as individual active substances or as a combination of many of these active substances. Preferred active substance combinations are mixtures of lavender oil, tea tree oil, cypress oil, and ABC-oil.
바람직한 방부제는 예컨대 1,1'-헥사메틸렌-비스-[5-(p-클로로페닐)-비구아나이드](클로르헥시딘)이 있다.Preferred preservatives are, for example, 1,1'-hexamethylene-bis- [5- (p-chlorophenyl) -biguanide] (chlorhexidine).
바람직한 코르티코스테로이드는 11β,16α,17α,21-테트라하이드록시-1,4-프레그나디엔-3,20-디온-16,17-아세톤아세탈(데소나이드), 9α,11β-디클로로-6α-플루오로-21-하이드록시-16α,17α-(이소프로필리덴디옥시)-프레그나-1,4-디엔-3,20-디온(플루클로로나이드; flucloronide), 6α,9α-디플루오르-16α,17α-이소프로필리덴디옥시-코르티코스테론(플루오시놀론 아세토나이드), 6α,9α-디플루오르-16α,17α-이소프로필리덴디옥시-코르티코스테론-아세테이트(플루오시노나이드), 6α-플루오르-11β,21-디하이드록시-16α,17-이소프로필리덴디옥시-4-프레그넨-3,20-디온(플루드록시코르티드), 3-(2-클로로에톡시)-9α-플루오로-6-포르밀-11β,21-디하이드록시-16α,17α-이소프로필리덴디옥시프레그나-3,5-디엔-20-온(포르모코르탈), 21-클로로-9α-플루오르-11β-하이드록시-16α,17α-이소프로필리덴디옥시-4-프레그넨-3,20-디온(할시노나이드), 트리암시놀론-16α,17α-아세토나이드(트리암시놀론 아세토나이드)이다.Preferred corticosteroids are 11β, 16α, 17α, 21-tetrahydroxy-1,4-pregnadiene-3,20-dione-16,17-acetoneacetal (desonide), 9α, 11β-dichloro-6α- Fluoro-21-hydroxy-16α, 17α- (isopropylidenedioxy) -pregna-1,4-diene-3,20-dione (fluchloronide; flucloronide), 6α, 9α-difluoro-16α , 17α-isopropylidenedioxy-corticosterone (fluorocinolone acetonide), 6α, 9α-difluoro-16α, 17α-isopropylidenedioxy-corticosterone-acetate (fluorinoid), 6α- Fluor-11β, 21-dihydroxy-16α, 17-isopropylidenedioxy-4-pregnene-3,20-dione (fludoxycortide), 3- (2-chloroethoxy) -9α-fluor Rho-6-formyl-11β, 21-dihydroxy-16α, 17α-isopropylidenedioxypregna-3,5-diene-20-one (formocortal), 21-chloro-9α-fluor -11β-hydroxy-16α, 17α-isopropylidenedi During a 4-frame geunen-3,20-dione (Halsey no-arsenide), triamcinolone -16α, 17α- acetonide (triamcinolone acetonide).
활성 물질의 조합물에 대한 특별한 예는 하기와 같다:Specific examples of combinations of active substances are as follows:
항진균제, 항생제, 혹은 방부제를 함유하는 코르티코스테로이드의 조합물. 바람직한 조합물은 예컨대 (±)-시스-1-아세틸-4-{4-([2-(2,4-디클로로페닐)-2-(1H-이미다졸-1-일메틸)-1,3-디옥소란-4-일]메톡시)페닐}-피페라진(케노코나졸)과 11β,16α,17α,21-테트라하이드록시-1,4-프레그나디엔-3,20-디온-16,17-아세톤아세탈(데소나이드)이다.Combination of corticosteroids containing antifungal, antibiotic, or preservatives. Preferred combinations are, for example, (±) -cis-1-acetyl-4- {4-([2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3 -Dioxoran-4-yl] methoxy) phenyl} -piperazine (kenokazole) and 11β, 16α, 17α, 21-tetrahydroxy-1,4-pregnadiene-3,20-dione- 16,17-acetone acetal (desonide).
천연 항진균제를 함유하는 합성 항진균제의 조합물. 바람직한 조합물은 티 트리 오일을 함유한 비스-페닐-(2-클로로-페닐)-1-이미다졸릴 메탄(클로트리마졸)이다.Combination of synthetic antifungal agents containing natural antifungal agents. Preferred combinations are bis-phenyl- (2-chloro-phenyl) -1-imidazolyl methane (clotrimazole) containing tea tree oil.
다양한 천연 항진균제의 조합물. 바람직한 조합물은 라벤더 오일, 티 트리 오일 및 ABC-오일(호주 블루 사이프러스 오일)이다.Combination of various natural antifungal agents. Preferred combinations are lavender oil, tea tree oil and ABC-oil (Australian blue cypress oil).
아미노산군, 비타민군 및 무기물질군으로부터 선택한 하나 혹은 그 이상의 추가 영양 및 재생 물질을 함유한 2-피롤리딘 카르본산(L-프롤린)의 조합물. 하나 혹은 그 이상의 영양 및 재생 물질을 함유한 2-피롤리딘 카르본산(L-프롤린)의 바람직한 조합물은 (S)-2,6-디아미노헥산산(라이신), (R)-2-아미노-3-메르캅토 프로피온산(사이스테인), 젤라틴, 시스-2-(4-카르복시부틸)-3,4-우레이도 테트라하이드로티오펜(ureido tetrahydro thiophene)(비오틴), (±)-2,4-디하이드록시-N-(3-하이드록시프로필)-3,3-디메틸 부티르아미드(판테놀), D(+)-2,4-디하이드록시-N-(3-하이드록시프로필)-3,3-디메틸부티르아미드(덱스판테놀), 그리고 무기질 혹은 유기질 칼슘 화합물, 마그네슘 화합물 혹은 아연 화합물이다.A combination of 2-pyrrolidine carboxylic acid (L-proline) containing one or more additional nutritional and regenerative substances selected from the group of amino acids, vitamins and inorganics. Preferred combinations of 2-pyrrolidine carboxylic acid (L-proline) containing one or more nutrients and regenerative substances are (S) -2,6-diaminohexanoic acid (lysine), (R) -2- Amino-3-mercapto propionic acid (cysteine), gelatin, cis-2- (4-carboxybutyl) -3,4-ureido tetrahydro thiophene (biotin), (±) -2, 4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethyl butyramide (panthenol), D (+)-2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethylbutyramide (dexpanthenol), and inorganic or organic calcium compounds, magnesium compounds or zinc compounds.
L-프롤린을 이용하여 재생 물질을 발견하였는데, 이는 손발톱 재생 및 손발톱 관리용으로 특히 적합한 것으로서 입증되었다. L-프롤린은 지금까지 활성 성분으로서 술폰화된 아미노산이나 혹은 술폰화된 아미노산의 유도체를 함유하는 손발톱 관리를 위한 화장용 약제의 선택적 성분으로만 언급되어 왔다(EP-A-0 534 810).L-proline was used to find regenerated material, which proved to be particularly suitable for nail regeneration and nail care. L-proline has been mentioned so far as an optional ingredient of cosmetic agents for nail care that contains sulfonated amino acids or derivatives of sulfonated amino acids as active ingredients (EP-A-0 534 810).
이하, 전술한 물질들은 위에서 괄호 안에 병기된 상응하는 관용명으로 지칭된다.In the following, the aforementioned substances are referred to by their corresponding common names written in parentheses above.
운반체로서 이용될 C1-C4-알킬에스테르는 메틸-, 에틸-, n-프로필-, 이소프로필-, n-부틸-, sec-부틸-, 이소부틸- 및 tert-부틸 에스테르를 함유하고 있다. 다가산인 사과산, 구연산 및 주석산의 에스테르의 경우 에스테르기 내에 함유된 C1-C4-알킬기는 동일하거나 상이할 수 있다. 전술한 다가산 내에서는 모든 카르복실기 혹은 이 카르복실기 중 오로지 일부만이 에스테르화될 수 있다. 그러므로, 사과산- 및 주석산 디-C1-C4-알킬에스테르와 더불어 또한 대응하는 사과산- 및 주석산 모노알킬에스테르도 고려된다. 구연산의 C1-C4-알킬에스테르 중에 대응하는 모노-, 디- 및 트리 알킬에스테르가 적합하다. 바람직한 에스테르는 에틸에스테르이다. 추가의 바람직한 에스테르는 이소프로필에스테르이다. 바람직한 단일 화합물은 유산 에틸에스테르이다. 추가의 바람직한 단일 화합물은 사과산 디에틸에스테르와 사과산 디이소프로필에스테르이다.C 1 -C 4 -alkylesters to be used as carriers contain methyl-, ethyl-, n-propyl-, isopropyl-, n-butyl-, sec-butyl-, isobutyl- and tert-butyl esters . In the case of esters of the polyacids malic acid, citric acid and tartaric acid, the C 1 -C 4 -alkyl groups contained in the ester groups can be the same or different. In the above-mentioned polyacid, all carboxyl groups or only some of these carboxyl groups can be esterified. Therefore, in addition to the malic acid- and tartaric acid di-C 1 -C 4 -alkylesters, the corresponding malic acid- and tartaric acid monoalkylesters are also contemplated. Corresponding mono-, di- and tri alkylesters in the C 1 -C 4 -alkyl esters of citric acid are suitable. Preferred esters are ethyl esters. Further preferred esters are isopropyl esters. Preferred single compounds are lactic ethyl ester. Further preferred single compounds are malic acid diethyl ester and malic acid diisopropyl ester.
본 발명에 따른 국소 도포 약제는 하나 혹은 그 이상의 활성 물질, 그리고 운반체로서 유산, 사과산, 주석산, 구연산, 운데칸산, 혹은 운데켄산의 하나 혹은 그 이상의 C1-C4-알킬에스테르와 더불어, 통상적인 생리학적 호환성 보조 첨가제를 함유할 수 있다. 이러한 유형의 적합한 보조 첨가제는 예컨데 테르펜이나 혹은 테르펜을 함유하는 오일, 알코올, 케톤, 지방산 에스테르, 폴리글리콜, 텐사이드, 요소, 산화 방지제, 및 복합제이다.Topical application agents according to the invention are conventional, in addition to one or more active substances and one or more C 1 -C 4 -alkylesters of lactic acid, malic acid, tartaric acid, citric acid, undecanoic acid, or undecanoic acid as carriers. It may contain physiologically compatible auxiliary additives. Suitable auxiliary additives of this type are, for example, terpenes or oils containing alcohols, alcohols, ketones, fatty acid esters, polyglycols, tensides, urea, antioxidants, and combinations.
적합한 테르펜은 비고리, 단고리 및 두고리형 테르펜, 및 이러한 테르펜을 함유하는 오일이다. 비고리형 테르펜에 대한 예는, 예컨대 미르켄과 같은 비고리형 테르펜 하이드로카본, 예컨대 시트로넬롤 및 게라니올과 같은 비고리형 테르펜 알코올 뿐 아니라, 예컨대 시트랄, α-Jonon, 및 β-Jonon과 같은 비고리형 테르펜 알데히드 및 테르펜 케톤이 있다. 단고리형 테르펜에 대한 예는 예컨대 α-테르피넨, γ-테르피넨 및 리모넨과 같은 단고리형 테르펜 하이드로카본, 예컨대 티몰, 멘톨, 시네올 및 카르바크롤과 같은 단고리형 테르펜 알코올 뿐 아니라 예컨대 멘톤 및 카르본과 같은 단고리형 테르펜 케톤이 있다. 두고리형 테르펜에 대한 예는 예컨대 카론과 같이 카란기로 이루어진 테르펜, 예컨대 α-피넨 및 β-피넨과 같이 피난기로 이루어진 테르펜, 뿐 아니라 예컨대 캄퍼 및 보르네올과 같이 보르난기로 이루어진 테르펜이 있다. 특히 적합한 테르펜은 예컨대 티몰 및 멘톨과 같은 단고리형 테르펜 알코올이다. 테르펜을 함유하는 적합한 오일에 대한 예는 페퍼민트 오일, 카르다모멘 오일(cardamomen oil), 게라늄 오일, 장미 오일, 측백나무 오일, 및 티미안 오일이 있다. 특히 적합한 오일은 페퍼민트 오일, 라벤더 오일 및 티미안 오일이다. 이미 언급한 바와 같이 측백나무 오일은 사마귀 제거에 특히 적합하다.Suitable terpenes are acyclic, monocyclic and bicyclic terpenes, and oils containing such terpenes. Examples for acyclic terpenes include, for example, acyclic terpene hydrocarbons such as mirkenes, for example acyclic terpene alcohols such as citronellol and geraniol, as well as for example citral, α-Jonon, and β-Jonon. Acyclic terpene aldehyde and terpene ketone. Examples for monocyclic terpenes are monocyclic terpene hydrocarbons such as, for example, α-terpinene, γ-terpinene and limonene, such as monocyclic terpene alcohols such as thymol, menthol, cinemaol and carbachol, as well as for example mentone and carbene. There is a monocyclic terpene ketone like this one. Examples of bicyclic terpenes include terpenes composed of caranic groups such as charon, for example terpenes composed of evacuation groups such as α-pinene and β-pinene, as well as terpenes composed of boran groups such as camphor and Borneol. Particularly suitable terpenes are monocyclic terpene alcohols such as thymol and menthol. Examples of suitable oils containing terpenes are peppermint oil, cardamomen oil, geranium oil, rose oil, cypress oil, and thyme oil. Particularly suitable oils are peppermint oil, lavender oil and thyme oil. As already mentioned, cypress oil is particularly suitable for wart removal.
적합한 알코올은 분지형이거나 비분지형 알코올로 1개 내지 3개의 하이드록시기 및 2개 내지 6개의 탄소 원자를 함유하되, 상기 하이드록시기는 부분적으로 혹은 완전하게 에테르화 및 에스테르화될 수 있다. 특히 적합한 알코올은 에탄올, 1-프로판올, 2-프로판올(이소프로판올), 1,2-프로판디올(프로필렌 글리콜), 2-페닐에탄올(페닐 에틸 알코올), 1-부탄올(부틸 알코올), 에틸렌 글리콜 모노메틸 에테르(메톡시 에탄올), 에틸렌 글리콜 모노페닐 에테르(페녹시 에탄올), 1,2,3-트리하이드록시프로판(글리세린), 에틸아세테이트, 부틸아세테이트, 글리세린 디아세테이트(디아세틴) 및 글리세린 트리아세테이트(트리아세틴)이다.Suitable alcohols are branched or unbranched alcohols containing from 1 to 3 hydroxy groups and from 2 to 6 carbon atoms, which hydroxyl groups can be partially or fully etherified and esterified. Particularly suitable alcohols are ethanol, 1-propanol, 2-propanol (isopropanol), 1,2-propanediol (propylene glycol), 2-phenylethanol (phenyl ethyl alcohol), 1-butanol (butyl alcohol), ethylene glycol monomethyl Ether (methoxy ethanol), ethylene glycol monophenyl ether (phenoxy ethanol), 1,2,3-trihydroxypropane (glycerine), ethyl acetate, butyl acetate, glycerin diacetate (diacetin) and glycerin triacetate ( Triacetin).
적합한 케톤으로서 예컨대 아세톤 및 메틸에틸케톤(2-부타논)이 고려된다.As suitable ketones, for example acetone and methylethylketone (2-butanone) are contemplated.
지방산 에스테르로서는 8개 내지 21개의 탄소 원자를 가지면서 포화 및 불포화된 분지형 및 비분지형 지방산의 에스테르가 적합하되, 알코올 성분은 1개 내지 6개의 탄소원자를 갖는 분지형 및 비분지형 알코올을 함유한다. 특히 적합한 지방산 에스테르는 트리데칸 카르본산 이소프로필 에스테르, 테트라데칸 카르본산 이소프로필 에스테르(이소프로필미리스테이트), 펜타데칸 카르본산 메틸에스테르 및 9-옥타데켄산 글리세린 모노에스테르(글리세린 모노올레에이트)이다.Suitable fatty acid esters are esters of saturated and unsaturated branched and unbranched fatty acids having 8 to 21 carbon atoms, with the alcohol component containing branched and unbranched alcohols having 1 to 6 carbon atoms. Particularly suitable fatty acid esters are tridecane carboxylic acid isopropyl ester, tetradecane carboxylic acid isopropyl ester (isopropyl myristate), pentadecane carboxylic acid methyl ester and 9-octadecanoic acid glycerin monoester (glycerine monooleate).
적합한 폴리글리콜은 예컨대 폴리글리콜 400이다.Suitable polyglycols are for example polyglycol 400.
적합한 텐사이드는 예컨대 비-이오노겐 표면 활성 물질이다. 특히 적합한 텐사이드는 소르비탄의 부분 지방산 에스테르(Span), 폴리옥시에틸렌소르비탄의 부분 지방산 에스테르(Tween), 폴리옥시에틸렌의 지방산 에스테르(Myrj), 및 폴리옥시에틸렌의 지방 알코올 에테르(Brij)이다.Suitable tensides are, for example, non-ionogen surface active materials. Particularly suitable tensides are partial fatty acid esters of sorbitan (Span), partial fatty acid esters of polyoxyethylene sorbitan (Tween), fatty acid esters of polyoxyethylene (Myrj), and fatty alcohol ethers of polyoxyethylene (Brij) .
적합한 산화 방지제는 예컨대 부틸하이드록시톨루올(BHT), 부틸-4-메톡시페놀(BHA), 토코페롤 및 아스코르베이트이다.Suitable antioxidants are, for example, butylhydroxytoluol (BHT), butyl-4-methoxyphenol (BHA), tocopherol and ascorbate.
복합제로서 적합한 물질은 예컨대 에틸렌 디아민 테트라 아세트산(EDTA) 및 디나트륨-에틸렌 디아민 테트라 아세트산(Na2-ETDA)이다.Suitable materials as co-agents are, for example, ethylene diamine tetra acetic acid (EDTA) and disodium-ethylene diamine tetra acetic acid (Na 2 -ETDA).
본 발명에 따른 국소 도포 약제로서 예컨대 용액, 팅크제, 에멀젼, 젤, 연고, 크림 및 페이스트가 고려된다. 바람직한 국소 투약 형태는 용액이다.As topical application agents according to the invention, for example solutions, tinctures, emulsions, gels, ointments, creams and pastes are contemplated. Preferred topical dosage forms are solutions.
본 발명은 또한 본 발명에 따른 국소 도포 약제를 제조하기 위한 방법에 관한 것으로, 보다 상세하게는 유산 에틸 에스테르와 하나 혹은 그 이상의 보조 첨가제를 균일하게 혼합하고, 이어서 이 혼합물에 하나 혹은 그 이상의 활성 물질을 휘저으면서, 경우에 따라 가열(최대 80℃)하면서 용해시키되, 균일한 활성 물질 용액이 생성될 때까지 계속 휘젓는 상기 방법에 관한 것이다. 획득된 용액은 바람직하게는 직접적으로 국소 도포를 위한 용액으로서 이용된다. 또한, 상기 용액은 통상적인 용해, 혼합 및 현탁 방법을 이용하여 추가의 생리학적 호환성 제형 보조 첨가제를 첨가하면서 또 다른 국소 투약 형태로 제조할 수 있다.The invention also relates to a method for the preparation of a topical medicament according to the invention, more particularly to homogeneously mixing the lactic ethyl ester with one or more auxiliary additives, followed by one or more active substances in the mixture. While stirring, dissolving while heating (up to 80 ° C.), if necessary, and continuing to stir until a homogeneous active substance solution is produced. The solution obtained is preferably used directly as a solution for topical application. The solution can also be prepared in another topical dosage form with the addition of additional physiologically compatible formulation auxiliary additives using conventional dissolution, mixing and suspension methods.
바람직하게는, 본 발명에 다른 국소 도포 약제는 용액의 형태로 사용된다. 바람직한 국소 도포 약제는 본 발명에 따라 하기 성분을 함유한다:Preferably, other topical application agents are used in the form of a solution. Preferred topical application agents contain the following ingredients according to the invention:
0.01 내지 20 중량%의 하나 혹은 그 이상의 활성 물질,0.01-20% by weight of one or more active substance,
1 내지 99.99 중량%의 유산, 사과산, 주석산, 혹은 구연산의 하나 혹은 그 이상의 C1-C4-알킬에스테르, 및1 to 99.99% by weight of one or more C 1 -C 4 -alkyl esters of lactic acid, malic acid, tartaric acid, or citric acid, and
0 내지 98.99 중량%의 하나 혹은 그 이상의 생리학적 호환성 보조 첨가제.0 to 98.99% by weight of one or more physiologically compatible auxiliary additives.
본 발명은 또한 사마귀, 손발톱 질병, 및 조갑주위 질병의 치료, 예방, 후속 치료 혹은 보조 치료 뿐 아니라 손발톱 관리를 위한 본 발명에 따른 국소 도포 약제의 용도에 관한 것이다. 그 외에도, 본 발명은 애완 동물 및 식용 가축의 발굽 및 발톱의 진균 감염을 치료하기 위한 본 발명에 따른 약제의 용도에 관한 것이다.The present invention also relates to the use of the topical medicament according to the invention for the treatment of nails, nail diseases, and peri-morbid diseases, as well as for the management of nails, as well as for the treatment of nails. In addition, the present invention relates to the use of a medicament according to the invention for the treatment of fungal infections of hooves and toenails of pets and edible livestock.
항진균제를 함유하는 국조 도포 약제는 예컨대 하기의 지시용으로 적합하다:Nationally applied coatings containing antifungal agents are suitable for the following indications, for example:
- 피부사상균, 효모 혹은 사상균 혹은 혼합 감염에 의해 야기되는 손발톱 진균증의 치료, 예방 및 후속 치료;-Treatment, prevention and subsequent treatment of nail fungus caused by dermatophytes, yeast or filamentous fungi or mixed infections;
- 건선, 당뇨병 혹은 AIDS를 앓고 있는 환자에게서 나타나는 손발톱 진균 감염의 치료, 예방 및 후속 치료;-Treatment, prevention and subsequent treatment of nail fungal infections in patients with psoriasis, diabetes or AIDS;
- 예컨대 칸디다 조갑주위염과 같은 조갑주위 손발톱 감염 치료의 보조.Aid in the treatment of periarticular nail infections, such as Candida periarthritis.
항생제를 함유하는 국소 도포 약제는 예컨대 하기의 지시용으로 적합하다:Topical medicaments containing antibiotics are suitable, for example, for the following indications:
- 박테리아에 의해 야기되는 손발톱 및 조갑주위 감염 치료 및/또는 예방의 보조.Aid in the treatment and / or prevention of nail and peri-parasitic infections caused by bacteria.
방부제를 함유하는 국소 도포 약제는 예컨대 하기 지시용으로 적합하다:Topical medicaments containing preservatives are suitable, for example, for the following indications:
- 비특정 혹은 구별되지 않은 병원체에 의해 야기되는 손발톱 및 조갑주위 감염의 치료 및 예방.-Treatment and prevention of nail and peri-parasitic infections caused by nonspecific or indistinguishable pathogens.
코르티코스테로이드, 또는 항진균제, 항생제 혹은 방부제를 포함하는 코르티코스테로이드 조합물을 함유하는 국소 도포 약제는 예컨대 하기의 지시용으로 적합하다:Topical medicaments containing corticosteroids or corticosteroid combinations comprising antifungal agents, antibiotics or preservatives are suitable, for example, for the following indications:
- 사마귀, 손발톱 건선 혹은 여타의 염증성 손발톱 및 조갑주위 상태의 치료, 예방, 후속 치료 혹은 보조 치료.Treatment, prevention, follow-up or adjuvant treatment of warts, nail psoriasis or other inflammatory nails and peri-conditions.
본 발명에 따른 약학상의 국소 도포 약제는 인체 손발톱에서의 사마귀, 손발톱 질병 및 조갑주위 질병을 치료하는 것 뿐 아니라, 애완 동물 및 식용 가축의 발굽 및 발톱의 질병을 치료하는데 적합하다. 상기 약학상 약제의 도포 주기는 질병의 크기 및 국소화에 따른다. 일반적으로 1일 1회 내지 3회의 도포로도 충분하다. 이와 관련하여, 용액은 질병이 있는 인체의 손발톱 또는 동물의 발굽 혹은 발톱 상에, 그리고 필요시 마찬가지로 결부되는 주변 피부 영역 상에 직접 도포된다. 치료는 재발을 억제하기 위해 증상이 사라진 후에도 약 2주간 더 계속하여야 한다.The pharmaceutical topical medicament according to the invention is suitable for treating warts, nail diseases and peri-morbid diseases in human nails, as well as for treating diseases of hooves and toenails of pets and edible livestock. The cycle of application of the pharmaceutical agent depends on the size and localization of the disease. Generally, one to three applications per day are sufficient. In this regard, the solution is applied directly on the toenails or animal hooves or toenails of the diseased human body and, if necessary, on the surrounding skin areas which are likewise joined. Treatment should be continued for about two weeks after symptoms disappear to prevent recurrence.
하나 혹은 그 이상의 영양 및 신진대사 물질을 함유하는 본 발명에 따른 화장용 국소 도포 약제는 예컨대 인체 손발톱의 손발톱 위축증(nail atrophy)에서와 같이 손발톱 관리에 적합하다. 손발톱 위축증은 예컨대 손발톱이 파손되고, 꺼칠꺼칠하고, 얇은 상태 뿐 아니라 점 형태 백색 반점 혹은 백색 줄무늬가 나타나는 것을 포함한다. 조성물은 미용상 보기 불쾌한 손발톱 상에, 그리고 필요시 그 주변 피부 영역 상에 도포된다. 상기 조성물의 도포 주기는 위축의 크기 및 국소화에 따른다. 일반적으로 1일 1회 내지 2회의 도포만으로도 충분하다.The cosmetic topical application according to the invention containing one or more nutritional and metabolic substances is suitable for nail care, such as in nail atrophy of human nails. Nail atrophy includes, for example, broken nails, stinging, and thinness, as well as the appearance of spot-shaped white spots or white streaks. The composition is applied on cosmetically unpleasant nails and, if necessary, on the surrounding skin area. The cycle of application of the composition depends on the size and localization of the atrophy. Generally, only one to two applications per day is sufficient.
본 발명에 따른 국소 도포 약제는 몇일 내에 활성 물질과 함께 질병이 있는 손발톱에 침투하여 조상 및 조근에서 작용할 수 있다는 장점을 갖는다. 보다 빠른 작용 개시 및 개선된 침투성에 의해 손발톱 질병의 치료는 대개 약 2개월 내지 3개월 이후에 종료된다. 그럼으로써 환자 순응도는 분명하게 개선되는데, 왜냐하면 여타의 치료방법에서 요구되는 오랜 치료 기간이 상당히 단축되기 때문이다. 질병이 있는 피부, 무엇보다 조갑주위 피부 영역에서 치유 과정 또는 관리 효과가 보다 빠르게 나타나는데, 왜냐하면 활성 물질이 효율적이면서 빠르게 피부 내로 흡수되기 때문이다. 손발톱 관리는 대개 한달간 실시하여야 한다. 또한, 건강한 손발톱 상태를 유지하려면 손발톱 관리 제품을 보다 오랜 기간에 걸쳐 사용할 수도 있다.The topical medicament according to the present invention has the advantage of being able to penetrate diseased nails with the active substance in a few days and act in the ancestors and roots. Treatment of nail disease is usually terminated after about two to three months due to faster onset of action and improved permeability. This clearly improves patient compliance, because the long duration of treatment required by other treatments is significantly shortened. In diseased skin and, above all, in the area around the peritoneal skin, the healing process or management effect is faster because the active substance is absorbed into the skin efficiently and quickly. Nail care should usually be done for a month. You can also use nail care products for longer periods of time to keep your nails healthy.
본 발명에 따른 국소 도포 약제는 몇일 내에 활성 물질과 함께 질병이 있는 손발톱에 침투하여 조상 및 조근에서 작용할 수 있다는 장점을 갖는다. 보다 빠른 작용 개시 및 개선된 침투성에 의해 손발톱 질병의 치료는 대개 약 2개월 내지 3개월 이후에 종료된다. 그럼으로써 환자 순응도는 분명하게 개선되는데, 왜냐하면 여타의 치료방법에서 요구되는 오랜 치료 기간이 본질적으로 단축되기 때문이다. 질병이 있는 피부, 무엇보다 조갑주위 피부 영역에서 치유 과정 또는 관리 효과가 보다 빠르게 나타나는데, 왜냐하면 활성 물질이 효율적이면서 빠르게 피부 내로 흡수되기 때문이다. The topical medicament according to the present invention has the advantage of being able to penetrate diseased nails with the active substance in a few days and act in the ancestors and roots. Treatment of nail disease is usually terminated after about two to three months due to faster onset of action and improved permeability. This clearly improves patient compliance because the long duration of treatment required by other treatments is inherently shortened. In diseased skin and, above all, in the area around the peritoneal skin, the healing process or management effect is faster because the active substance is absorbed into the skin efficiently and quickly.
본 발명은 하기의 실시예에 의해 보다 상세하게 설명된다:The invention is illustrated in more detail by the following examples:
실시예 1: 클로트리마졸-용액 1% Example 1 Clotrimazole-Solution 1%
유산 에틸에스테르 20.0mlLactic acid ethyl ester 20.0ml
요소 2.0g2.0 g of urea
클로트리마졸 1.0gClotrimazole 1.0 g
유산 에틸에스테르 ad 100.0mlLactic acid ethyl ester ad 100.0ml
100ml의 플라스크 내에서 20ml의 유산 에틸에스테르에 요소를 첨가하여 휘젓고 가열(약 50℃)하면서 용해시킨다. 이 용해된 용액에 클로트리마졸을 휘저으면서 첨가한다. 그런 다음 100ml가 되도록 유산 에틸에스테르를 추가 첨가한다. 균일한 용액이 되도록 계속해서 휘젓는다.Urea is added to 20 ml of lactic acid ethyl ester in a 100 ml flask, and the solution is stirred and heated (about 50 ° C.). Clotrimazole is added to this dissolved solution while stirring. Then add lactic ethyl ester to 100 ml. Continue stirring to ensure a uniform solution.
실시예 2: 측백나무 오일 2.0 % Example 2: 2.0% cypress oil
유산 에틸에스테르 98.0 %Lactic acid ethyl ester 98.0%
실시예 3: 측백나무 오일 2.0 % Example 3: 2.0% cypress oil
티 트리 오일 1.0 %Tea tree oil 1.0%
유산 2.0 %Heritage 2.0%
유산 에틸에스테르 95.0 %Lactic acid ethyl ester 95.0%
실시예 4: 측백나무 오일 2.0 % Example 4: 2.0% cypress oil
살리실산 2.0 %Salicylic acid 2.0%
사과산 에틸에스테르 96.0 %Malic Acid Ethyl Ester 96.0%
실시예 5: 시클로피록스올아민 8.0 % Example 5: Cyclopyroxolamine 8.0%
유산 에틸에스테르 92.0 %Lactic acid ethyl ester 92.0%
실시예 6: 에탄올 5.0 % Example 6: 5.0% Ethanol
운데켄산 10.0 %Undekenic acid 10.0%
구연산 메틸에스테르 85.0 %Citric acid methyl ester 85.0%
실시예 7: 라벤더 오일 2.0 % Example 7: Lavender Oil 2.0%
운데켄산 10.0 %Undekenic acid 10.0%
유산 에틸에스테르 88.0 %Lactic acid ethyl ester 88.0%
실시예 8: 클로트리마졸-티 트리 오일-용액 1% + 1% Example 8: clotrimazole-tea tree oil-solution 1% + 1%
유산 에틸에스테르 20.0 ml20.0 ml of lactic acid ethyl ester
요소 2.0 g2.0 g of elements
클로트리마졸 1.0 g1.0 g of clotrimazole
티 트리 오일 1.0 gTea tree oil 1.0 g
유산 에틸에스테르 ad 100.0 mlLactic acid ethyl ester ad 100.0 ml
100ml의 플라스크 내에서 20ml의 유산 에틸에스테르에 요소를 휘젓고 가열(약 50℃)하면서 용해시킨다. 이어서 앞서 용해된 용액에 휘저으면서 클로트리마졸 및 티 트리 오일을 첨가한 다음 용액이 100ml가 되도록 유산 에틸에스테르를 추가 첨가한다. 균일한 용액이 형성될 때까지 계속해서 휘젓는다.The urea is stirred in 20 ml of lactic acid ethyl ester in a 100 ml flask and dissolved with heating (about 50 ° C.). Then, clotrimazole and tea tree oil are added while stirring in the previously dissolved solution, and then lactic ethyl ester is further added so that the solution is 100 ml. Continue stirring until a uniform solution is formed.
실시예 9: 티 트리 오일-라벤더 오일-용액 1.0% Example 9: Tea Tree Oil-Lavender Oil-Solution 1.0%
유산 에틸에스테르 44.0 g44.0 g of lactic acid ethyl ester
티 트리 오일 1.0 gTea tree oil 1.0 g
라벤더 오일 6.0 g6.0 g of lavender oil
프로필렌글리콜 20.0 g20.0 g of propylene glycol
모든 물질들을 계량하여 비이커 그라스에 담고 균일한 용액이 형성될 때까지 휘젓는다.All materials are weighed and placed in a beaker glass and stirred until a homogeneous solution is formed.
실시예 10: ABC-오일-용액 2% Example 10 ABC-oil-solution 2%
ABC-오일 2.0 gABC-oil 2.0 g
프로필렌글리콜 20.0 g20.0 g of propylene glycol
유산 에틸에스테르 72.0 gLactic acid ethyl ester 72.0 g
티 트리 오일 1.0 gTea tree oil 1.0 g
라벤더 오일 5.0 g5.0 g of lavender oil
균일한 용액이 이루어질 때까지 혼합물을 계속해서 휘젓는다.Stir the mixture continuously until a homogeneous solution is achieved.
실시예 11: 프롤린-용액 1.5% Example 11: Proline-Solution 1.5%
L-프롤린 1.5 g1.5 g of L-proline
프로필렌글리콜 65.0 g65.0 g of propylene glycol
유산 에틸에스테르 33.5 g33.5 g of lactic acid ethyl ester
L-프롤린을 프로필렌글리콜에 넣고 휘젓고 가열하면서 용해시킨다. 이어서 유산 에틸에스테르를 첨가하여 균일한 용액이 달성될 때까지 계속해서 휘젓는다.L-proline is added to propylene glycol and stirred to dissolve while heating. Lactic ethyl ester is then added and stirring is continued until a uniform solution is achieved.
실시예Example 12: 12:
L-프롤린 2.0 g2.0 g of L-proline
사과산 디에틸에스테르 93.0 g93.0 g of malic acid diethyl ester
이소프로필알코올 5.0 g5.0 g of isopropyl alcohol
L-프롤린을 휘저으면서 사과산 디에틸에스테르에 첨가하고 완전하게 용해될 때까지 추가로 휘젓는다.The L-proline is added to the malic acid diethyl ester with agitation and further stirred until completely dissolved.
실시예Example 13: 13:
다음의 도표에는 추가의 본 발명에 따른 조성물이 제시되어 있다. 이러한 조성물은 본 발명에 따라 운반체로서 이용될 각각 50.0g의 하이드록시카르본산-C1-C4-알킬에스테르, 및 각각 1.0g의 활성 물질을 이용하여 획득된다. 상기 조성물을 제조하기 위해, 주변 온도 혹은 적당하게 상승된 온도(~ 30℃ - 50℃)에서 휘저으면서 하이드록시카르본산 에스테르 내에 각각의 활성 물질을 첨가하였다. 각각의 활성 물질에 따라 1시간 내지 5시간의 후속교반 후에 투명하면서도 바로 사용이 가능한 용액이 획득되는데, 이와 관련하여 활성 물질의 각각의 용해도에 따라 2 내지 5%의 저급 알칸올을 가용화제로서 첨가하였다.In the following diagrams further compositions according to the invention are presented. Such compositions are obtained using 50.0 g of hydroxycarboxylic acid-C 1 -C 4 -alkylesters each to be used as a carrier according to the invention, and 1.0 g of active substance each. To prepare the composition, each active material was added to the hydroxycarboxylic acid ester while stirring at ambient or moderately elevated temperature (˜30 ° C.-50 ° C.). A clear yet ready-to-use solution is obtained after 1 to 5 hours of subsequent stirring for each active substance, in which 2-5% of lower alkanol is added as a solubilizer, depending on the solubility of the active substance. It was.
실시예Example 14: 14:
다음의 도표에는 추가의 본 발명에 따른 조성물이 제시되어 있으며, 이러한 조성물은 본 발명에 따라 운반체로서 이용될 각각 92.0g의 하이드록시카르본산-C1-C4-알킬에스테르와, 5g의 라벤더 오일, 1.0g의 티 트리 오일 및 2g의 ABC 오일로 이루어진 8.0g의 활성 물질 조합물을 이용하여 획득된다. 상기 조성물은 주변 온도 조건에서 각각 사용되는 하이드록시카르본산에스테르에 활성 물질 조합물을 휘저으면서 첨가함으로써 제조된다. 상기와 같이 획득된 조성물은 곧바로 사용이 가능하다.The following table shows further compositions according to the invention, each comprising 92.0 g of hydroxycarboxylic acid-C 1 -C 4 -alkylester and 5 g of lavender oil to be used as a carrier according to the invention. , 8.0 g of active material combination consisting of 1.0 g of tea tree oil and 2 g of ABC oil. The composition is prepared by stirring the active substance combination into the hydroxycarboxylic acid esters respectively used at ambient temperature conditions. The composition obtained as above can be used immediately.
Claims (1)
a) 하나 혹은 그 이상의 활성 물질,
b) 운반체로서 유산, 사과산, 주석산, 구연산, 운데칸산, 혹은 운데켄산의 하나 혹은 그 이상의 C1-C4-알킬에스테르, 및
c) 경우에 따라 생리학적으로 적합한 보조 첨가제.A method of treating warts with a non-aqueous topical application containing the following substances:
a) one or more active substances,
b) one or more C 1 -C 4 -alkyl esters of lactic acid, malic acid, tartaric acid, citric acid, undecanoic acid, or undecanoic acid as carriers, and
c) optionally a physiologically suitable auxiliary additive.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140026061A KR20140048908A (en) | 2014-03-05 | 2014-03-05 | Topical formulation to be applied to wart removal, nail-disease treatment and nail care |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140026061A KR20140048908A (en) | 2014-03-05 | 2014-03-05 | Topical formulation to be applied to wart removal, nail-disease treatment and nail care |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120133794A Division KR20130001197A (en) | 2012-11-23 | 2012-11-23 | Topical formulation to be applied to wart removal, nail-disease treatment and nail care |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140048908A true KR20140048908A (en) | 2014-04-24 |
Family
ID=50654756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140026061A KR20140048908A (en) | 2014-03-05 | 2014-03-05 | Topical formulation to be applied to wart removal, nail-disease treatment and nail care |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20140048908A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096506A (en) * | 2017-12-29 | 2018-06-01 | 罗起超 | One kind is dispelled wart Chinese medicinal plant extracting solution and preparation method thereof |
-
2014
- 2014-03-05 KR KR1020140026061A patent/KR20140048908A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096506A (en) * | 2017-12-29 | 2018-06-01 | 罗起超 | One kind is dispelled wart Chinese medicinal plant extracting solution and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5170486B2 (en) | Topically applicable product | |
US7135194B2 (en) | Subunguicide, and method for treating onychomycosis | |
CA2683958C (en) | Topical fungicidal agents for treating nail disorders | |
JPWO2007077806A1 (en) | Pharmaceutical composition for nail | |
KR20140048908A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
KR20060104011A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
AU2005203232B2 (en) | Topical formulations for the treatment of papillary tubercles, nail diseases and nail care | |
KR20130001197A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
RU2351312C2 (en) | Pharmaceutical and cosmetic compositions intended for hand nail treatment | |
BE1018742A3 (en) | COMPOSITION FOR TREATMENT OF NAIL MEL DISEASES AND USE THEREOF. | |
TWI520729B (en) | Topische formulierungen fuer anwendung bei warzen, nagelerkrankungen und zur nagelpflege | |
CN1939539A (en) | Local prescription for wart, nail-disease treatment and nail care | |
CN103357015A (en) | Local preparation for removing verruca and nail diseases and taking care of nails | |
MXPA05005429A (en) | Topical formulations for treating warts, finger nail diseases, and nail care | |
TW201622710A (en) | Topical formulation for the treatment of papillary tubercles, nail diseases and nail care | |
NL2016203B1 (en) | Composition and device for the treatment of fungal nails. | |
MXPA06003354A (en) | Pharmaceutical and cosmetic formulations for treating fingernails |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |